These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 32681915)

  • 1. Sacral Nerve Stimulation in Parkinson's Disease Patients With Overactive Bladder Symptoms.
    Greenberg DR; Sohlberg EM; Zhang CA; Santini VE; Comiter CV; Enemchukwu EA
    Urology; 2020 Oct; 144():99-105. PubMed ID: 32681915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of Sacral Nerve Stimulation for Treatment of Refractory Overactive Bladder Among Octogenarians.
    Greenberg DR; Syan R; Young-Lin N; Comiter CV; Enemchukwu E
    Neuromodulation; 2019 Aug; 22(6):738-744. PubMed ID: 31215713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Clinical and Urodynamic Results of Percutaneous Posterior Tibial Nerve Stimulation on Neurogenic Detrusor Overactivity in Patients With Parkinson's Disease.
    Kabay S; Canbaz Kabay S; Cetiner M; Mestan E; Sevim M; Ayas S; Ozden H; Ozisik Karaman H
    Urology; 2016 Jan; 87():76-81. PubMed ID: 26436213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urethral instability and sacral nerve stimulation-a better parameter to predict efficacy?
    Groenendijk PM; Heesakkers JP; Lycklama A Nijeholt AA
    J Urol; 2007 Aug; 178(2):568-72; discussion 572. PubMed ID: 17570438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five-Year Followup Results of a Prospective, Multicenter Study of Patients with Overactive Bladder Treated with Sacral Neuromodulation.
    Siegel S; Noblett K; Mangel J; Bennett J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Zylstra S; Kan F; Berg KC
    J Urol; 2018 Jan; 199(1):229-236. PubMed ID: 28709886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sacral Nerve Stimulation for Pediatric Lower Urinary Tract Dysfunction: Development of a Standardized Pathway with Objective Urodynamic Outcomes.
    Schober MS; Sulkowski JP; Lu PL; Minneci PC; Deans KJ; Teich S; Alpert SA
    J Urol; 2015 Dec; 194(6):1721-6. PubMed ID: 26141849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urodynamic changes and response rates in patients treated with permanent electrodes compared to conventional wire electrodes in the peripheral nerve evaluation test.
    Bannowsky A; Wefer B; Braun PM; Jünemann KP
    World J Urol; 2008 Dec; 26(6):623-6. PubMed ID: 18629503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study.
    Peters KM; Carrico DJ; Wooldridge LS; Miller CJ; MacDiarmid SA
    J Urol; 2013 Jun; 189(6):2194-201. PubMed ID: 23219541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Underactive and overactive bladders are related to motor function and quality of life in Parkinson's disease.
    Liu Z; Uchiyama T; Sakakibara R; Yamamoto T
    Int Urol Nephrol; 2015 May; 47(5):751-7. PubMed ID: 25792006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of lower urinary tract symptoms in patients with Parkinson's disease.
    Badri AV; Purohit RS; Skenazy J; Weiss JP; Blaivas JG
    Curr Urol Rep; 2014 Sep; 15(9):435. PubMed ID: 25002072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long term safety of sacral nerve modulation in medicare beneficiaries.
    Chughtai B; Sedrakyan A; Isaacs A; Lee R; Te A; Kaplan S
    Neurourol Urodyn; 2015 Sep; 34(7):659-63. PubMed ID: 25066920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Onset of Action of Sacral Neuromodulation in Lower Urinary Tract Dysfunction-What is the Optimal Duration of Test Stimulation?
    Jairam R; Drossaerts J; Marcelissen T; van Koeveringe G; van Kerrebroeck P
    J Urol; 2018 Jun; 199(6):1584-1590. PubMed ID: 29291416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is sacral neuromodulation effective in patients with Parkinson's disease? A retrospective review.
    Martin S; Zillioux J; Goldman HB
    Neurourol Urodyn; 2022 Apr; 41(4):955-961. PubMed ID: 35238421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do Patients Discontinue Overactive Bladder Medications after Sacral Neuromodulation?
    Amin K; Moskowitz D; Kobashi KC; Lee UJ; Lucioni A
    J Urol; 2019 May; 201(5):973-978. PubMed ID: 30694936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sacral nerve stimulation for voiding dysfunction: One institution's 11-year experience.
    Sutherland SE; Lavers A; Carlson A; Holtz C; Kesha J; Siegel SW
    Neurourol Urodyn; 2007; 26(1):19-28; discussion 36. PubMed ID: 17078071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Sacral neuromodulation in urology. The emperor's new clothes or effective high-tech medicine?].
    Hoda MR; Fornara P
    Urologe A; 2010 Oct; 49(10):1254-9. PubMed ID: 20859609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of urodynamic tools to guide patient selection in sacral neuromodulation.
    Drossaerts J; Rademakers K; van Koeveringe G; Van Kerrebroeck P
    World J Urol; 2015 Nov; 33(11):1889-95. PubMed ID: 25680936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The management of overactive bladder: percutaneous tibial nerve stimulation, sacral nerve stimulation, or botulinum toxin?
    Tubaro A; Puccini F; De Nunzio C
    Curr Opin Urol; 2015 Jul; 25(4):305-10. PubMed ID: 26049873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and adverse events of sacral nerve stimulation for overactive bladder: A systematic review.
    Siddiqui NY; Wu JM; Amundsen CL
    Neurourol Urodyn; 2010; 29 Suppl 1():S18-23. PubMed ID: 20419795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determining outcomes, adverse events, and predictors of success after sacral neuromodulation for lower urinary disorders in women.
    Yazdany T; Bhatia N; Nguyen J
    Int Urogynecol J; 2011 Dec; 22(12):1549-54. PubMed ID: 21796469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.